ReviewJournal of inflammation research2026
Icariin as a Metabolic Regulator of Bone Marrow Mesenchymal Stem Cells: Mechanisms and Therapeutic Implications to Bone Homeostasis.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epimedium and its principal bioactive flavonoid, Icariin (ICA), are recognized as significant regulators of bone metabolism. ICA is well-documented for its ability to enhance osteogenesis and suppress osteoclastogenesis, yet its capacity to influence cellular metabolic pathways is a burgeoning field of investigation. The differentiation of bone marrow mesenchymal stem cells (BMSC) into either osteogenic or adipogenic lineages is intricately associated with intrinsic metabolic alterations, the dysregulation of which is a pivotal factor in the pathogenesis of osteoporosis. This review, conducted following a systematic literature search and quality assessment utilizing Joanna Briggs Institute (JBI) tools, examines the potential of ICA to modulate the osteogenic-adipogenic equilibrium of BMSC. Given that much of the extant evidence concerning direct metabolic reprogramming is indirect, we integrate insights from recent molecular studies to propose mechanisms by which ICA may interact with critical BMSC pathways, particularly glycolysis and fatty acid metabolism. Ultimately, we assess the therapeutic prospects of modulating BMSC metabolism with ICA, and we identify prospective directions for its clinical application in the management of bone disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.